The CIML is proud to announce that Temper Bio, co-founded by Sophie Ugolini, Inserm Research Director and team leader at CIML, has been awarded the prestigious i-Lab prize for its innovative project aimed at treating inflammatory diseases.
Temper Bio, co-founded and funded by Argobio Studio, is developing innovative analogues of the neurokine TAFA4 for breakthrough treatments of chronic inflammatory diseases. The award-winning program aims to expand the therapeutic potential of TAFA4 to neuroinflammation, an emerging therapeutic field addressing a significant medical need. This recognition highlights the excellence and potential of the research conducted by Sophie Ugolini and her team. This is the second major distinction within a year, following the securing of Impulscience funding. https://www.argobiostudio.com/en/portfolio/temper-bio

su